Cencora SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 4, 2026, 9:25 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCencora Recasts Reporting Structure into Three Segments for Fiscal 2027; Revised Fiscal 2026 Total Revenue of $337.4 billion and Segment Operating Income of $4.81 billion Disclosed
8-KNov. 4, 2026, 6:37 a.m. ETView on SEC.gov Our explainer
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCencora Q4 Adjusted EPS $4.66 Beats $4.57 Consensus, but FY2027 Adjusted EPS Guidance of $19.40-$19.75 Sits Below $19.76 Consensus
8-KOct. 21, 2026, 7:48 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCencora to acquire American Oncology Network for $2.3 billion at closing plus up to $100 million CVRs; raises low end of FY2026 adjusted EPS to at least $17.90
8-KSept. 25, 2026, 8:11 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
8-KAug. 14, 2026, 4:06 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 12, 2026, 12:38 p.m. ETView on SEC.gov
Regulation FD disclosure
8-KAug. 5, 2026, 6:32 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
8-KAug. 5, 2026, 6:45 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Creation of a direct financial obligation · Financial statements and exhibits